Imunon Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $5,838,566 | $11,492,841 |
| Investment in debt securities - available for sale, at fair value | 9,857,087 | 21,254,485 |
| Accrued interest receivable on investment securities | - | 128,932 |
| Money market investments, restricted cash | - | 1,500,000 |
| Advances and deposits on clinical programs and other current assets | 2,545,051 | 2,403,433 |
| Total current assets | 18,240,704 | 36,779,691 |
| Property and equipment (at cost, less accumulated depreciation and amortization) | 751,906 | 548,301 |
| Other assets: | ||
| Money market investments, restricted cash | - | 4,500,000 |
| Deferred income tax asset | 1,280,385 | 1,567,026 |
| Operating lease right-of-use assets, net | 1,595,074 | 155,876 |
| Deposits and other assets | 50,000 | 425,000 |
| Total other assets | 2,925,459 | 6,647,902 |
| Total assets | $21,918,069 | $43,975,894 |
CONSOLIDATED BALANCE SHEETS
(Continued)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable – trade | $3,515,192 | $3,586,623 |
| Other accrued liabilities | 3,390,521 | 4,794,936 |
| Notes payable – current portion, net of deferred financing costs | - | 1,424,774 |
| Operating lease liabilities - current portion | 485,421 | 230,749 |
| Total current liabilities | 7,391,134 | 10,037,082 |
| Notes payable – non-current portion, net of deferred financing costs | - | 4,610,946 |
| Operating lease liabilities - non-current portion | 1,139,293 | - |
| Total liabilities | 8,530,427 | 14,648,028 |
| Commitments and contingencies | – | – |
| Stockholders’ equity: | ||
| Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at December 31, 2023 and 2022) | – | – |
| Common stock - $0.01 par value (112,500,000 shares authorized; 9,399,811 and 7,436,219 shares issued at December 31, 2023 and 2022, respectively, and 9,399,789 and 7,436,197 shares outstanding at December 31, 2023 and 2022, respectively) | 93,998 | 74,362 |
| Additional paid-in capital | 401,500,838 | 397,980,023 |
| Accumulated other comprehensive income | 60,796 | 26,494 |
| Accumulated deficit | (388,182,802) | (368,667,825) |
| Total stockholders’ equity before treasury stock | 13,472,830 | 29,413,054 |
| Treasury stock, at cost (22 shares at December 31, 2023 and 2022) | (85,188) | (85,188) |
| Total stockholders’ equity | 13,387,642 | 29,327,866 |
| Total liabilities and stockholders’ equity | $21,918,069 | $43,975,894 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.